See more : J-Lease Co.,Ltd. (7187.T) Income Statement Analysis – Financial Results
Complete financial analysis of Genmab A/S (GNMSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genmab A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Motive Capital Corp II (MTVC-WT) Income Statement Analysis – Financial Results
- Hathway Bhawani Cabletel & Datacom Limited (HATHWAYB.BO) Income Statement Analysis – Financial Results
- BOK Financial Corporation (BOKF) Income Statement Analysis – Financial Results
- Medpace Holdings, Inc. (MEDP) Income Statement Analysis – Financial Results
- Inner Mongolia MengDian HuaNeng Thermal Power Corporation Limited (600863.SS) Income Statement Analysis – Financial Results
Genmab A/S (GNMSF)
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.47B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | 350.94M | 582.08M | 586.08M | 745.11M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Cost of Revenue | 226.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 532.51M | 582.51M | 0.00 | 48.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.25B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | -181.57M | -435.00K | 586.08M | 696.30M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Gross Profit Ratio | 98.63% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -51.74% | -0.07% | 100.00% | 93.45% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 7.63B | 5.56B | 4.18B | 3.14B | 2.39B | 1.43B | 874.28M | 660.88M | 487.66M | 505.68M | 527.58M | 536.70M | 532.51M | 0.00 | 935.36M | 1.42B | 618.50M | 359.95M | 304.10M | 373.33M | 345.98M | 396.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.30B | 2.68B | 1.28B | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.93B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 67.85M | 160.25M | 1.08B | 1.35B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Cost & Expenses | 11.15B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 600.36M | 742.77M | 1.08B | 1.39B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Interest Income | 939.00M | 324.00M | 197.00M | 184.00M | 120.00M | 62.92M | 41.43M | 32.58M | 37.26M | 38.33M | 28.61M | 17.83M | 3.49M | 1.40M | 181.10M | 126.67M | 155.11M | 46.25M | 34.78M | 42.52M | 68.68M | 53.39M |
| Interest Expense | 27.00M | 21.00M | 13.00M | 10.00M | 7.00M | 417.00K | 2.80M | 213.00K | 118.00K | 4.05M | 3.33M | 2.72M | 43.09M | 39.65M | 25.05M | 220.83M | 1.15M | 1.03M | 1.35M | 68.58M | 83.71M | 100.37M |
| Depreciation & Amortization | 240.00M | 290.00M | 250.00M | 246.00M | 139.00M | 87.70M | 47.54M | 40.96M | 31.82M | 12.33M | 11.66M | 15.11M | 15.05M | 21.03M | 83.78M | 85.09M | 14.25M | 17.50M | 31.78M | 53.66M | 63.67M | 47.47M |
| EBITDA | 5.56B | 7.04B | 3.46B | 6.76B | 2.78B | 1.47B | 1.46B | 1.09B | 585.98M | 277.51M | 80.92M | -96.25M | -192.75M | -61.76M | -77.11M | -516.46M | -317.72M | -419.70M | -360.46M | 537.46M | 474.56M | 669.75M |
| EBITDA Ratio | 33.76% | 48.26% | 40.83% | 66.82% | 53.99% | 50.60% | 61.53% | 62.02% | 70.56% | 37.14% | 16.51% | -17.28% | -43.23% | -10.61% | -39.78% | -75.66% | -55.57% | -306.70% | -355.83% | 13,105.49% | 694.55% | 0.00% |
| Operating Income | 5.32B | 6.36B | 3.02B | 6.31B | 2.64B | 1.38B | 1.34B | 1.05B | 730.38M | 265.18M | 69.25M | -116.68M | -249.42M | -160.69M | -498.03M | -870.00M | -437.13M | -472.21M | -427.92M | 441.27M | -342.21M | -483.08M |
| Operating Income Ratio | 32.30% | 43.56% | 35.58% | 62.44% | 49.16% | 45.63% | 56.83% | 57.97% | 64.46% | 31.18% | 10.44% | -24.08% | -71.07% | -27.61% | -84.98% | -116.76% | -82.55% | -348.38% | -434.42% | 10,760.13% | -500.85% | 0.00% |
| Total Other Income/Expenses | 316.00M | 768.00M | 1.03B | -409.00M | 221.00M | 232.00M | -280.45M | 77.38M | 27.15M | 32.17M | -3.85M | 2.60M | 39.59M | 38.25M | 156.05M | -94.84M | 53.76M | 33.98M | 34.33M | -26.06M | -15.03M | 962.08M |
| Income Before Tax | 5.64B | 7.04B | 3.98B | 5.90B | 2.86B | 1.61B | 1.06B | 1.13B | 757.53M | 297.35M | 65.40M | -114.08M | -209.83M | -122.44M | -341.99M | -964.51M | -383.37M | -438.24M | -393.59M | 415.21M | 327.18M | 479.00M |
| Income Before Tax Ratio | 34.22% | 48.20% | 46.96% | 58.39% | 53.28% | 53.29% | 44.97% | 62.23% | 66.86% | 34.97% | 9.86% | -23.54% | -59.79% | -21.04% | -58.35% | -129.44% | -72.40% | -323.31% | -399.56% | 10,124.65% | 478.85% | 0.00% |
| Income Tax Expense | 1.29B | 1.51B | 975.00M | 1.15B | 693.00M | 139.83M | -39.83M | -56.86M | -5.99M | -3.95M | -4.75M | -2.63M | 5.92M | 20.87M | 5.91M | 583.00K | 128.62M | 38.99M | 45.64M | 872.94M | -66.00K | 326.00K |
| Net Income | 4.35B | 5.45B | 2.96B | 4.76B | 2.17B | 1.47B | 1.10B | 1.19B | 763.51M | 301.30M | 112.36M | -487.12M | -596.37M | -321.46M | -1.01B | -965.09M | -383.37M | -438.24M | -393.59M | -415.21M | -327.11M | -479.33M |
| Net Income Ratio | 26.42% | 37.36% | 34.86% | 47.06% | 40.37% | 48.66% | 46.67% | 65.36% | 67.39% | 35.43% | 16.93% | -100.51% | -169.94% | -55.23% | -172.46% | -129.52% | -72.40% | -323.31% | -399.56% | -10,124.65% | -478.75% | 0.00% |
| EPS | 66.02 | 83.38 | 46.00 | 73.00 | 34.40 | 24.03 | 18.14 | 19.83 | 13.05 | 5.35 | 2.20 | -10.58 | -13.28 | -7.16 | -22.51 | -21.62 | -8.72 | -11.26 | -12.59 | -15.69 | -14.33 | -21.46 |
| EPS Diluted | 66.02 | 82.59 | 45.54 | 72.22 | 34.04 | 23.72 | 17.77 | 19.22 | 12.56 | 5.26 | 2.16 | -10.58 | -13.28 | -7.16 | -22.51 | -21.62 | -8.72 | -11.26 | -12.59 | -15.69 | -14.33 | -21.46 |
| Weighted Avg Shares Out | 65.92M | 65.39M | 65.40M | 65.18M | 62.96M | 61.27M | 60.83M | 59.88M | 58.52M | 56.32M | 50.98M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
| Weighted Avg Shares Out (Dil) | 65.91M | 66.01M | 66.05M | 65.89M | 63.64M | 62.04M | 62.09M | 61.77M | 60.77M | 57.25M | 51.91M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Source: https://incomestatements.info
Category: Stock Reports